

**AMENDMENTS TO THE CLAIMS UNDER 37 C.F.R. § 1.121(c)(1)**


Please cancel claims 1-14 without prejudice.

Please add new claims 15-22.

A complete version of the entire set of pending claims under 37 C.F.R. § 1.121(c)(3) is as follows:

1-14. (CANCELED)

15. (NEW) A compound having the formula:



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>6</sub> are each independently selected from the group consisting of hydrogen, CH<sub>2</sub>OH, CHO, and CH<sub>2</sub>NH<sub>2</sub>;


Y is selected from the group consisting of selenium, sulfur, oxygen, and NR, wherein R is hydrogen or C<sub>1</sub>-C<sub>7</sub> alkyl;

and when at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, or R<sub>6</sub> is CH<sub>2</sub>NH<sub>2</sub>, a pharmaceutically acceptable salt of the compound represented thereby; with the proviso that when R<sub>1</sub> and R<sub>2</sub> are both hydrogen, R<sub>3</sub> and R<sub>6</sub> are not both hydrogen.

16. (NEW) The compound of claim 15, wherein R<sub>3</sub> and R<sub>6</sub> are hydrogen.

17. (NEW) The compound of claim 15, wherein the compound is complexed with a cyclodextrin.

18. (NEW) A compound having the formula:




wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>6</sub> are each independently selected from the group consisting of hydrogen, CHO, CH<sub>2</sub>OH, and CH<sub>2</sub>NH<sub>2</sub>;

Y is selected from the group consisting of selenium, sulfur, oxygen, and NR, wherein R is hydrogen or C<sub>1</sub>-C<sub>7</sub> alkyl;

and when at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, or R<sub>6</sub> is CH<sub>2</sub>NH<sub>2</sub>, a pharmaceutically acceptable salt of the compound represented thereby; with the proviso that R<sub>1</sub> and R<sub>2</sub> are not both hydrogen.

19. (NEW) The compound of claim 18, wherein the compound is complexed with a cyclodextrin.

20. (NEW) A pharmaceutical composition comprising a compound having the formula:



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>6</sub> are each independently selected from the group consisting of hydrogen, CH<sub>2</sub>OH, CHO, and CH<sub>2</sub>NH<sub>2</sub>;

Y is selected from the group consisting of selenium, sulfur, oxygen, and NR, wherein R is hydrogen or C<sub>1</sub>-C<sub>7</sub> alkyl;

and when at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, or R<sub>6</sub> is CH<sub>2</sub>NH<sub>2</sub>, a pharmaceutically acceptable salt of the compound represented thereby; with the proviso that at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, or R<sub>6</sub> is other than hydrogen;

and a pharmaceutically acceptable carrier.

21. (NEW) The composition of claim 20, wherein R<sub>3</sub> and R<sub>6</sub> in the compound are hydrogen.

22. (NEW) The pharmaceutical composition of claim 20, wherein the compound is complexed with a cyclodextrin.